Pulmonary nodule
Conditions
Interventions
Sugammadex group:If T2 appears, 2 mg/kg of sugammadex is administered to antagonize neuromuscular blockade. If T2 does not appear but the post-tetanic count (PTC) is greater than 0, a dose of 4 mg/kg
Neostigmine group:Antagonism is administered when T2 appears, with neostigmine at a dose of 0.04 mg/kg, combined with atropine at a dose of 0.02 mg/kg.
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age = 65 years, no gender restrictions 2.ASA classification I-III 3.Patients scheduled for elective thoracoscopic lobectomy
Exclusion criteria
Exclusion criteria: 1.Patients with severe underlying liver or kidney disease, or severe heart disease 2.Patients with drug allergies or contraindications to neostigmine and atropine 3.Patients with a history of preoperative lung infection, COPD, asthma, or bronchiectasis 4.Patients who voluntarily request to withdraw from the study during the trial 5.Patients with preoperative cognitive impairment, dementia, Parkinson’s disease, or other mental disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative recovery quality assessed using the QoR-15 scale score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative pulmonary complications (PPCs);Nausea and vomiting;Incidence of hypoxia;Incidence of postoperative residual neuromuscular blockade; | — |
Countries
China
Contacts
Public ContactHao Jiao
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed